Handelsavisen
prelaunch
Companies Financials SFES.PK
SF
SFES.PK OTC Diversified Investment Management

Safeguard Scientifics Inc

$0,40
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
-15,4 %
Net margin
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Safeguard Scientifics Inc is a diversified holding company that invests in and manages a portfolio of technology and life sciences businesses, primarily generating revenue through equity stakes and operational income from its subsidiaries.

Business. Safeguard Scientifics Inc (SFES.PK) is a diversified investment management firm operating within the Financials sector. The company generates revenue primarily through fee-based models associated with asset management activities. It is listed on the OTC market under the ticker SFES.PK. Specific details regarding operating segments, headquarters location, and geographic breakdowns are not provided in the available data.

Classification99 %
SectorFinancials
Industry groupDiversified Investment Management
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-15,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SFES.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials · THIS SECTOR−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SFES.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Safeguard Scientifics Inc (SFES.PK) is a diversified investment management firm operating within the Financials sector. The company generates revenue primarily through fee-based models associated with asset management activities. It is listed on the OTC market under the ticker SFES.PK. Specific details regarding operating segments, headquarters location, and geographic breakdowns are not provided in the available data.

    Classification99 %
    SectorFinancials
    Industry groupDiversified Investment Management
    AI synthesis
    GENERATED

    Safeguard Scientifics Inc exhibits a strong capital structure with a current ratio of 22.67, indicating a high level of liquidity and the ability to cover short-term liabilities many times over. The company has no long-term debt, and its cash and equivalents amount to $19.4 million, which is a significant portion of its total assets of $46.2 million. This liquidity position is further supported by a debt-to-equity ratio of 0.0, suggesting a conservative capital structure with no leverage.

    Profitability metrics for Safeguard Scientifics Inc are negative, with a return on equity (ROE) of -15.41% and a return on assets (ROA) of -14.52%. These figures indicate that the company is not generating returns for its shareholders and is underperforming relative to industry norms. The negative operating income of $1.23 million and net income of -$6.71 million further underscore the company's current unprofitability.

    The company's revenue is derived from a diversified portfolio of technology and life sciences businesses, though specific segment details are not disclosed in the available data. Geographically, the company's exposure is not explicitly outlined, but its operations are likely concentrated in the United States given its listing and primary market.

    Looking ahead, the company's growth trajectory is uncertain. The current fiscal year is expected to show a continuation of the negative trends, with no significant improvement in operating cash flow, which was -$1.00 million in the latest period. The lack of positive cash flow and the absence of long-term debt suggest that the company is not currently expanding through capital-intensive projects or acquisitions.

    Risk factors for Safeguard Scientifics Inc include its unprofitable operations and the potential for continued negative returns on equity and assets. The company's liquidity is strong, but its profitability is a concern. There is no immediate dilution risk, as the number of shares outstanding has not changed between basic and diluted shares. The company has not made any recent adjustments to its valuation metrics, and there are no filing-based liquidity or dilution flags.

    Recent events for Safeguard Scientifics Inc include the latest financial reporting period, which shows a continuation of the company's unprofitable operations. There are no recent filings or transcripts indicating significant changes in strategy or operations. The company's focus remains on managing its portfolio of investments and subsidiaries, with no immediate plans for major restructuring or expansion.

    Key takeaways
    • Safeguard Scientifics Inc has a strong liquidity position with a current ratio of 22.67 and no long-term debt.
    • The company is currently unprofitable, with a negative return on equity and assets.
    • There is no immediate dilution risk, as the number of shares outstanding has not changed.
    • The company's growth trajectory is uncertain, with no significant improvement in operating cash flow.
    • The company's operations are likely concentrated in the United States, with a focus on technology and life sciences businesses.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2020-02-27
    Q4 2019 · Quarter highlights

    Operating income -$1.0M.

    Revenue
    Operating income-$1.0M
    Net income-$4.9M
    Free cash flow
    EPS
    Operating cash flow-$3.3M
    Financials
    Income statement
    Revenue
    Gross profit
    Operating income-$1.0M
    Net income-$4.9M
    Balance sheet
    Total assets$37.7M
    Total liabilities$3.1M
    Total equity$34.6M
    Cash & equivalents$13.3M
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$3.3M
    CapEx
    Free cash flow
    SBC
    Highlights
    • Operating income -$1.0M

    Valuation TTM

    Market price
    $0,40
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $43.5M
    Net cash
    $19.4M
    Current ratio
    22.7
    Debt / equity
    0.0
    ROA
    -14.5%
    ROE
    -15.4%
    Cash conversion
    15.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Asset Management
    low · business_description · 2026-07-04
    Investment Advisory
    low · business_description · 2026-07-04

    Market share

    INDUSTRYSEGMENTCOMPANYFinancialsIndustryDiversified Investment Management225,8B node revenueBN 33,3%BLK 10,7%KKR 8,6%AMP 8,4%BX 6,4%STT 6,2%BEN 3,9%BPYPP 3,2%Other 19,4%
    Source: company disclosures · own-taxonomy revenue-covered setSFES 0,0% · rank #33 of 44

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs SFES · multiples and returns
    BN
    BN
    Brookfield Corp
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BL
    BLK
    Blackrock Inc
    $1 126,63
    185,9B USD
    P/E
    32,7x
    vs self
    Div yield
    1,9 %
    vs self
    ROE
    9,8 %
    vs self
    KK
    KKR
    Kkr & Co Inc
    $106,56
    94,8B USD
    P/E
    37,9x
    vs self
    Div yield
    0,7 %
    vs self
    ROE
    7,8 %
    vs self
    AM
    AMP
    Ameriprise Financial Inc
    $552,07
    52,2B USD
    P/E
    14,0x
    vs self
    Div yield
    vs self
    ROE
    57,4 %
    vs self
    BX
    BX
    Blackstone Inc
    $134,68
    105,9B USD
    P/E
    31,7x
    vs self
    Div yield
    3,8 %
    vs self
    ROE
    36,1 %
    vs self
    ST
    STT
    State Street Corp
    $183,67
    52,0B USD
    P/E
    18,2x
    vs self
    Div yield
    1,7 %
    vs self
    ROE
    10,6 %
    vs self
    BE
    BEN
    Franklin Resources Inc
    $35,24
    18,2B USD
    P/E
    31,8x
    vs self
    Div yield
    4,0 %
    vs self
    ROE
    4,5 %
    vs self
    BP
    BPYPP
    Brookfield Property Partners L.P.
    $15,87
    116,8M USD
    P/E
    vs self
    Div yield
    10,1 %
    vs self
    ROE
    -4,0 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-15,4 %Bottom quartile
    D/E0,00Above median
    Cash Conv0,15Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Safeguard Scientifics Inc Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    42.6Kshares short-3.0% vs prior
    9.74days to cover
    606fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SFES.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Operating income (YoY) (2023-12-31 vs 2022-12-31): -19.0%Derived (calculated)
    • EPS (basic) (YoY) (2023-12-31 vs 2022-12-31): 29.9%Derived (calculated)
    • Total liabilities (YoY) (2023-12-31 vs 2022-12-31): -8.3%Derived (calculated)
    • Total assets (YoY) (2023-12-31 vs 2022-12-31): -39.4%Derived (calculated)
    • EPS (diluted) (YoY) (2023-12-31 vs 2022-12-31): 29.9%Derived (calculated)
    • Current ratio (FY 2023-12-31): 4.84xDerived (calculated)
    • Cash & equivalents (YoY) (2023-12-31 vs 2022-12-31): -28.8%Derived (calculated)
    • Operating cash flow (YoY) (2023-12-31 vs 2022-12-31): -1.5%Derived (calculated)
    • EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
    • Pre-tax income (annual): USD -9.83MSEC XBRL filing
    • Current liabilities (annual): USD 2.05MSEC XBRL filing
    • Operating cash flow (annual): USD -3.31MSEC XBRL filing
    • Current assets (annual): USD 9.91MSEC XBRL filing
    • Total assets (annual): USD 22.84MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
    • Total liabilities (annual): USD 2.86MSEC XBRL filing
    • Cash & equivalents (annual): USD 9.5MSEC XBRL filing
    • Operating income (annual): USD -5.68MSEC XBRL filing
    • EPS (basic) (YoY) (2022-12-31 vs 2021-12-31): -164.0%Derived (calculated)
    • Operating income (YoY) (2022-12-31 vs 2021-12-31): 33.2%Derived (calculated)
    • Total assets (YoY) (2022-12-31 vs 2021-12-31): -30.2%Derived (calculated)
    • Total liabilities (YoY) (2022-12-31 vs 2021-12-31): -10.0%Derived (calculated)
    • Cash & equivalents (YoY) (2022-12-31 vs 2021-12-31): -46.1%Derived (calculated)
    • EPS (diluted) (YoY) (2022-12-31 vs 2021-12-31): -164.0%Derived (calculated)
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2020-02-27 06:00 UTCEARNINGSQuarterly results — Q4 2019 Net USD -4.9M
    2020-02-27 06:00 UTCEARNINGSAnnual results — FY 2020 Net USD -14.3M
    2019-11-07 06:00 UTCEARNINGSQuarterly results — Q3 2019 Net USD -3.2M
    2019-08-08 06:32 UTCEARNINGSQuarterly results — Q2 2019 Net USD 0.5M
    2019-05-02 06:00 UTCEARNINGSQuarterly results — Q1 2019 Net USD -6.7M
    2019-02-28 06:00 UTCEARNINGSAnnual results — FY 2019 Net USD 27.0M
    2018-03-01 06:22 UTCEARNINGSAnnual results — FY 2018 Net USD -37.6M
    2017-03-02 06:00 UTCEARNINGSAnnual results — FY 2017 Net USD 54.6M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage